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Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed
psychiatric disorders in childhood. A wide variety of treatments have been used for the man-
agement of ADHD. We aimed to compare the efficacy and safety of pharmacological, psy-
chological and complementary and alternative medicine interventions for the treatment of
ADHD in children and adolescents.
Methods and findings
We performed a systematic review with network meta-analyses. Randomised controlled trials
( 3 weeks follow-up) were identified from published and unpublished sources through
searches in PubMed and the Cochrane Library (up to April 7, 2016). Interventions of interest
were pharmacological (stimulants, non-stimulants, antidepressants, antipsychotics, and other
unlicensed drugs), psychological (behavioural, cognitive training and neurofeedback) and
complementary and alternative medicine (dietary therapy, fatty acids, amino acids, minerals,
herbal therapy, homeopathy, and physical activity). The primary outcomes were efficacy (treat-
ment response) and acceptability (all-cause discontinuation). Secondary outcomes included
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discontinuation due to adverse events (tolerability), as well as serious adverse events and spe-
cific adverse events. Random-effects Bayesian network meta-analyses were conducted
to obtain estimates as odds ratios (ORs) with 95% credibility intervals. We analysed inter-
ventions by class and individually. 190 randomised trials (52 different interventions
grouped in 32 therapeutic classes) that enrolled 26114 participants with ADHD were
included in complex networks. At the class level, behavioural therapy (alone or in combi-
nation with stimulants), stimulants, and non-stimulant seemed significantly more effica-
cious than placebo. Behavioural therapy in combination with stimulants seemed superior
to stimulants or non-stimulants. Stimulants seemed superior to behavioural therapy, cog-
nitive training and non-stimulants. Behavioural therapy, stimulants and their combination
showed the best profile of acceptability. Stimulants and non-stimulants seemed well toler-
ated. Among medications, methylphenidate, amphetamine, atomoxetine, guanfacine and
clonidine seemed significantly more efficacious than placebo. Methylphenidate and
amphetamine seemed more efficacious than atomoxetine and guanfacine. Methylpheni-
date and clonidine seemed better accepted than placebo and atomoxetine. Most of the
efficacious pharmacological treatments were associated with harms (anorexia, weight
loss and insomnia), but an increased risk of serious adverse events was not observed.
There is lack of evidence for cognitive training, neurofeedback, antidepressants, antipsy-
chotics, dietary therapy, fatty acids, and other complementary and alternative medicine.
Overall findings were limited by the clinical and methodological heterogeneity, small
sample sizes of trials, short-term follow-up, and the absence of high-quality evidence;
consequently, results should be interpreted with caution.
Conclusions
Clinical differences may exist between the pharmacological and non-pharmacological treat-
ment used for the management of ADHD. Uncertainties about therapies and the balance
between benefits, costs and potential harms should be considered before starting treatment.
There is an urgent need for high-quality randomised trials of the multiple treatments for
ADHD in children and adolescents. PROSPERO, number CRD42014015008.
Introduction
Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed psy-
chiatric disorders in children and adolescents. Recent estimates suggest that ADHD affects
about 3–7% of young people worldwide [1–2], producing considerable impact on health ser-
vices and the community [3–5]. ADHD is a childhood-onset disorder characterized by a per-
sistent pattern of symptoms of developmentally inappropriate and impaired inattention and/
or hyperactivity/impulsivity, with difficulties often continuing into adulthood. The diagnosis
of the disorder also requires the presence of symptoms across more than one setting (e.g.,
home and school) and requires that the symptoms needed for diagnosis result in academic,
social, or occupational impairment [6–8].
In recent years, the management of ADHD has become increasingly complex as new thera-
pies are introduced in clinical practice. The comparative efficacy and safety of pharmacological
and non-pharmacological treatments are largely unknown, mainly because of the paucity of
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head-to-head trials. A wide variety of interventions have been used for the treatment of
ADHD, including pharmacological and psychological interventions, herbal and homeopathic
remedies, and dietary management. Despite the extensive body of research into the epidemiol-
ogy and pathophysiology of ADHD, less emphasis has been placed on methodologically sound
comparative research questions evaluating and comparing different ADHD treatment options.
For example, which ADHD treatment modality works best in children and adolescents, psy-
chological interventions, pharmacological therapy or both? Among broad groups of treatment
interventions, is there any particular treatment which is clinically superior (or inferior) to oth-
ers? Is there a unique role of complementary and alternative medicine used in the treatment of
children and adolescents with ADHD? Although the evidence is not strong, pharmacological
treatment using stimulant medication is generally recommended for school-age children and
adolescents with ADHD, along with implementation of psychological interventions based on
behavioural approaches [9–11]. Very frequently, however, parents consider using complemen-
tary and alternative medicine as a therapeutic option for controlling the core ADHD symp-
toms. Randomised trials and systematic reviews have evaluated the effects of pharmacological
and non-pharmacological interventions in children and adolescents with ADHD [12–19], but
most research has been limited to a particular treatment approach only without considering all
available treatment alternatives, comparators and outcome measures of clinical importance.
Knowledge gaps in the current evidence base present opportunities for the application of
novel evidence synthesis methods to complex networks of trials and interventions, as well as
rigorous comparative evaluations of multiple treatments for ADHD. Relatively new methods
have been developed to analyse such complex trial data, including network meta-analysis,
which helps to integrate and synthesise diverse results to determine the relative merits of mul-
tiple treatments. Network meta-analysis has been recommended as a next generation tool for
evidence synthesis when a heterogeneous set of treatments and trials is included in the same
review [20–24]. Network meta-analysis may also be of particular use when included interven-
tions are not only heterogeneous, but complex in nature (e.g., treatments that may operate
through a variety of causal pathways) [23, 25–28]. To our knowledge, none of the previous
research has attempted to establish evidence-based comparative effects of all pharmacological
and non-pharmacological ADHD treatments in a comprehensive systematic review using net-
work meta-analyses.
Accordingly, we aimed to compare the efficacy and safety of pharmacological, psychological
and complementary and alternative medicine interventions for the treatment of ADHD in
children and adolescents. We used network meta-analyses comparing multiple interventions
to integrate direct and indirect evidence into unified networks of all available randomised
trials.
Methods
This systematic review was conducted and reported in accordance with the reporting guidance
provided in the PRISMA statement extension for systematic reviews incorporating network
meta-analysis [29] (S1 Checklist). We developed a systematic review protocol and registered
with PROSPERO (CRD42014015008) [30]. Our methods are briefly described here (and
explained in more detail in S1 Text and in the published protocol [30]).
Eligibility criteria
We included randomised controlled trials which: (1) had at least three weeks follow-up (three
weeks per treatment arm in parallel-group trials and three weeks in the first randomisation
period for crossover studies) as this is the minimum length of treatment chosen in trials
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designed to measure dose responses or efficacy; (2) compared pharmacological or non-phar-
macological interventions against each other or against placebo/control in the treatment of
children and adolescents (under 18 years of age) with a diagnosis of ADHD (e.g., following the
Diagnostic and Statistical Manual of Mental Disorders [DSM] criteria or the International
Classification of Diseases [ICD]). All ADHD subtypes (e.g., combined type, predominantly
inattentive and predominantly hyperactive/impulsive) were considered for inclusion. We
included trials that enrolled patients with comorbid conditions (such as oppositional defiant,
conduct disorder, anxiety, depression, epilepsy or other ADHD associated medical condi-
tions). Eligible interventions were pharmacological, psychological, complementary and alter-
native medicine, and combined interventions. Pharmacological interventions were not
required to be licensed for ADHD. Control conditions were placebo or no treatment, waitlist
(in psychological studies), and usual care or control (however defined in the trials) (see Box 1
Box 1. Brief description of interventions being evaluated
Pharmacological interventions. Pharmacological interventions refer to the treatment of
ADHD using medication, under the supervision of a medical professional. Studies evalu-
ating any of the following drugs at any therapeutic dose were considered: Stimulants
(e.g., methylphenidate, amphetamine); Non-stimulants (e.g., atomoxetine, guanfacine,
clonidine, antidepressants (e.g., bupropion, venlafaxine, reboxetine, desipramine, imip-
ramine); Antipsychotics (e.g., risperidone, aripiprazole, thioridazine); Other unlicensed
drugs (e.g. modafinil, carbamazepine).
Psychological interventions. A diverse range of psychological therapies is available
for the treatment of ADHD in children and adolescents. Psychological interventions
were: Behavioural therapy: an intervention directed at changing behaviours (increasing
desired behaviours and decreasing undesired behaviours), based on social learning prin-
ciples and other cognitive theories. These include classical contingency management,
behaviour therapy (mainly through mediators such as parents or teachers) and cognitive
behaviour therapy (such as verbal self-instruction, problem solving strategies or social
skills training). These treatments are usually offered in several sessions over time, either
through training the parents (teachers) or the child or both. Cognitive training: working
memory training incorporating adaptive schedules that are hypothesized to strengthen
ADHD-deficient neuropsychological processes. We retained studies including training
interventions that aim to directly train a cognitive function, or working memory, or
attention (e.g. working memory training, attention training). Neurofeedback using the
visualization of brain activity to teach children to increase attention and impulse control.
Neurofeedback is commonly based on electroencephalography; sensors are placed on
the scalp to measure activity, and measurements displayed using video displays or
sound. By learning to control their brain activity based on behavioural principles of
operant conditioning, it is hypothesized that ADHD patients will learn to regulate the
associated attentional states and processes.
Complementary and alternative medicine interventions. Complementary and
alternative medicine is a group of diverse medical and health care systems, practices and
products that are not presently considered to be part of conventional medicine. A
diverse range of interventions are being used for the treatment of ADHD in children
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for definitions of interventions). We assumed that patients who fulfilled the inclusion criteria
were equally eligible to be randomised to any of the interventions of interest.
The pre-specified primary outcomes were treatment response and all-cause treatment dis-
continuation rates, chosen because they are among the most clinically meaningful and consis-
tently reported estimates of treatment efficacy and acceptability in mental health research
[30,31]. We defined response as the proportion of patients who displayed improvements in the
symptoms of ADHD or global functioning on standardized rating scales–e.g., pre-defined cut-
off points for this specific age group such as ‘much improved’ or ‘very much improved’ on the
clinical global impression (CGI), or a reduction of at least 25% from the baseline score on the
ADHD Rating Scale (ADHD-RS). When trials reported results from multiple rating scales, we
used CGI results as the preferred scale. Clinicians, teachers or parents, and patients rated
symptoms and global functioning. As per our review protocol [30], clinician rated measures
were given preference in the primary analyses of treatment response. We defined all-cause
discontinuation (acceptability) as the proportion of patients who left the study early for any
reason, measured at the longest available follow-up. Secondary outcomes were treatment toler-
ability, serious adverse events and specific adverse events, respectively. We defined tolerability
as the proportion of patients who have left the study early due to adverse events, measured at
the longest available follow-up. Serious adverse events were defined as the occurrence of any
untoward medical event that resulted in death, was life-threatening, required inpatient hospi-
talization or prolonged existing hospitalization, resulted in persistent or significant disability/
incapacity, or was an important medical event. Specific adverse events of interest included the
occurrence of anorexia (or loss of appetite), weight loss (or decreased weight gain), insomnia,
sleep disturbances (unspecified), anxiety, syncope, and any cardiovascular adverse event.
Electronic literature search
We used a staged approach to study identification, beginning with a systematic search of rele-
vant trials included in systematic reviews available in PubMed/MEDLINE (January 1, 2005 –
April 7, 2016), the Cochrane Database of Systematic Reviews (The Cochrane Library, issue 4 of
12, April 2016) and/or existing meta-analyses of which we were aware (S2 Text for details of
search terms and S3 Text for references of previous reviews) with no language restrictions.
PubMed/MEDLINE was next searched to identify other additional relevant trials published
and adolescents: Dietary therapy, such as restricted elimination diet or ‘few foods
approach’ (exclusion of items associated with food hypersensitivity, sometimes referred
to as an oligoantigenic diet) and artificial food colour elimination from child’s diet (e.g.
removing food colours such as azo dyes, tartrazine, carmoisine, sunset yellow, brilliant
blue, indigotine, allura red, quinoline yellow or ponceau 4R); Polyunsaturated fatty acids
(PUFA e.g. omega-3 and omega-6 fatty acids); Vitamins (e.g., vitamin B6, vitamin B9,
vitamin B12, vitamin C);Minerals (e.g., magnesium, zinc, iron, calcium); Amino acids
(e.g., acetyl-L-carnitine, gamma-aminobutyric acid, glycine, L-tyrosine). Herbal therapy
(e.g., Ginkgo Biloba, Ginseng, St John’s Wort/Hypericum perforatum, Valerian);Homeo-
pathic treatment and any other supplementary interventions;Mind- and body-based
interventions (such as physical activity or exercise).
Control comparators. Eligible control conditions were: Placebo (psychological or
pill), waiting list (in psychological studies), and control (usual care, conventional therapy
or control).
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outside the time frames of previous reviews (up to May 6, 2016). We compiled a list of the
unique PubMed/MEDLINE identification numbers of all relevant articles, and performed a
related articles search. This technique has been shown to be highly effective in identifying rele-
vant studies [32], increases efficiency in study identification in the presence of an already large
evidence base and is being used as part of an ongoing network meta-analysis research program
[33,34]. Searches were supplemented by consulting alternative databases (PsycINFO and
AMED), public clinical trial registers (e.g., www.clinicaltrials.gov) and manufacturer clinical
trial registers (e.g., www.lillytrials.com and www.shiretrials.com), regulatory agencies websites
(e.g., the European Medicines Agency and the U.S. Foods and Drug Administration), and
review of references of relevant papers, health technology assessment reports and clinical prac-
tice guidelines. We contacted authors for missing outcome data or unclear information. Fur-
thermore, we contacted the European Medicines Agency for unpublished data through its
recent transparency policy [35].
Screening, data extraction and risk of bias assessment
Eligible trials identified from our searching efforts were independently screened by two
reviewers, first at the abstract level and then at the full text level for those considered poten-
tially eligible. Using a predesigned form that was piloted on a small sample (n = 30; 16%) of
studies, two reviewers were responsible for independent data extraction on general character-
istics (e.g. average age, gender, subtype and duration of ADHD, initial severity, patient comor-
bidity history, past medication use with stimulants, mean or median follow-up) and outcome
data. The Cochrane Risk of Bias tool [36] that considers sequence generation, allocation con-
cealment, and masking and other aspects of bias, was used to assess each included study’s risk
of bias. The overall rating of risk of bias for each study was the worst rating for any of the crite-
ria (e.g., if any domain is scored high risk of bias, the study was considered high risk of bias).
Risk of bias assessments were independently performed by two of four reviewers. We used the
Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method-
ology [37,38] to evaluate the quality of evidence for each outcome. Quality of evidence was
adjudicated as high (further research is very unlikely to change our confidence in the estimate
of effect), moderate (further research is likely to have an important impact on our confidence
in the estimate of effect and may change the estimate), low (further research is very likely to
have an important impact on our confidence in the estimate of effect and is likely to change
the estimate), or very low (very uncertain about the estimate of effect). This approach for grad-
ing the strength of the body of evidence was consistent with previous reporting of network
meta-analyses of healthcare interventions [33,39]. Any discrepancies between reviewers for
any of the above steps were discussed until consensus was achieved.
Geometry of the evidence networks assessed
We analysed interventions by class (e.g., behavioural therapy, stimulants, non-stimulants, etc.)
and individually (e.g., parent training, methylphenidate, etc.). In general, treatments with simi-
lar mechanisms of action were classified in classes in which treatment effects were considered
to be similar. Our primary class-level analyses classified therapeutic class interventions used in
monotherapy and/or combination as separate treatment nodes irrespective of their doses: con-
trols (placebo, usual care/control and waiting list), psychological interventions (behavioural
therapy such as parent training, child training and teacher training; cognitive training including
attention training and working memory training; neurofeedback; other psychotherapies), phar-
macological interventions (stimulants including methylphenidate and amphetamines; non-
stimulants including atomoxetine, guanfacine and clonidine; antidepressants; antipsychotics
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and other unlicensed drugs) and complementary and alternative medicine interventions (die-
tary therapy such as elimination diet; polyunsaturated fatty acids; amino acids; minerals; herbal
therapy; homeopathy; and physical activity). For the primary outcomes, we expressed compara-
tive effects of therapeutic class interventions using placebo as the reference comparator. Addi-
tionally, we also expressed individual effects of commonly prescribed pharmacological
interventions [40] using methylphenidate as the reference treatment, because methylphenidate
has been used for the treatment of ADHD for over 50 years and is now the most frequently pre-
scribed drug for ADHD worldwide [13].
Methods for evidence synthesis
Whenever possible we used results from intention-to-treat analyses in which the original ran-
dom participant assignment was maintained in the data analyses. For each outcome, we pre-
sented graphically the geometry of the treatment network of all comparisons [41]. Using a
Bayesian framework, we performed network meta-analyses for each pre-specified outcome
and treatment. Network meta-analyses [42,43] allow the integration of direct and indirect evi-
dence to increase precision while randomisation is preserved, but can also be used to estimate
comparisons between pairs of treatments that have not been compared in individual trials.
Network meta-analyses rely on the assumptions of transitivity (that is, one can learn about
treatment A versus treatment B via a common comparator C) and consistency (equivalency of
treatment effects from direct and indirect evidence) [29,44]. We used random effects network
meta-analysis models as recommended elsewhere assuming a common heterogeneity parame-
ter across all comparisons, accounting for correlations in multi-arm studies [45] and using
vague (non-informative) prior distributions for all treatment effects. We reported the results
as posterior median odds ratios (ORs) with corresponding 95% credibility intervals (CrIs),
which are the Bayesian analogue of 95% CIs. Network meta-analyses were generally based on a
total of 40,000 iterations or more with a burn-in of 20,000 iterations. We assessed convergence
on the basis of Brooks–Gelman–Rubin plots [46]. To calculate direct estimates of treatment
effect, we conducted pairwise random-effects meta-analyses for primary outcomes. We
reported the results as odds ratios (ORs) and corresponding 95% confidence intervals (CIs).
Statistical heterogeneity was assessed by the I2 index [47] and the Cochran’s Q chi-square test
[48]. Small study effect bias (sometimes referred to publication bias) was examined with the
use of funnel plots and the Begg’s adjusted rank correlation test [49,50]. Consistency was
examined by fitting both consistency and inconsistency models [51] for network meta-analysis
and comparing the deviance information criteria (DIC) between models, with smaller values
indicative of a better fit and a difference of five or more being considered as important. In gen-
eral, when both models had a similar fit to the data as indicated by their DIC values, we con-
cluded that there was no evidence of inconsistency. League table structure has been used to
present the findings from network meta-analyses.
Sensitivity analyses performed
Sensitivity analyses were conducted to explore the impact of potentially important effect modi-
fiers on findings from network meta-analysis. These included separate analyses that involved
exclusion of the following: studies at overall high risk of bias, studies where both the assessor
and the patient (or caregiver) were unmasked (commonly called ‘unblinded’ trials), and small
studies (with less than 100 participants). Other pre-planned analyses were the extension of the
primary unadjusted network meta-analysis model to include covariates in meta-regression
models [52] that considered the following: year of publication, study duration (follow-up),
mean age of trial participants, % of male participants, and baseline risk (e.g., response rate in
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placebo as a proxy of medical history, severity, comorbidities or other unmeasured underlying
factors). Several subgroup analyses for treatment response effects included: type of scale
(ADHD symptoms-based compared to global functioning-based rating scale) and type of rater
(clinicians compared to other). Because of the chronic course of ADHD, we also analysed stud-
ies of different durations separately in relation to response outcome measured during initial
short-term treatment (the first 6 weeks of treatment with a range of 3 to 12 weeks), mid-term
treatment (24 weeks of treatment with a range of 13 to 48 weeks) and long-term treatment
(more than 48 weeks). In addition, sensitivity analyses of the geometry of treatment networks
were conducted including the dosage of stimulants (amphetamine low to moderate dose 20
mg/day compared to high dose>20 mg/day; methylphenidate low to moderate dose 30 mg/
day compared to high dose >30 mg/day) and type of formulations (short-acting compared to
long-acting preparations).
Software considerations
All Bayesian network meta-analyses were conducted using WinBUGS 1.4.3 (MRC Biostatistics
Unit, Cambridge, UK), while pairwise meta-analyses and network diagrams were generated
using Stata 13 (StataCorp LP, College Station, Texas, USA).
Results
Extent of relevant literature identified
The systematic search identified 5,606 citations (from 116 systematic reviews and updated
searches), of which 804 were examined in full-text review and 540 were excluded. Accordingly,
we included 190 studies (described in 264 publications). A PRISMA flowchart documenting the
process of study selection is shown in S1 Fig, while the full reference listing of included studies
is provided in S4 Text. Studies included a total of 26,114 participants randomly assigned to one
of the study treatments or control conditions; details of the included studies (including general
characteristics of patients such as average age, gender distribution, study follow-up, treatment
comparisons, etc.) are shown in S1–S5 Tables. Key characteristics are described next.
Overview of study and patient characteristics
The mean duration of follow-up of included studies was 12 weeks (range 3–96) and the mean
sample size was 137 (range 9–1323), with 91 trials (47.9%) having at least 100 participants and
7 trials (3.8%) having more than 400. Studies assessed 52 interventions or control conditions,
which were grouped in 32 therapeutic classes (125 trials evaluated pharmacological interven-
tions, 48 trials evaluated psychological interventions and 39 trials their combinations). Most
studies (86%) included two groups; while smaller totals included three groups (11%) or more
(3%). Most studies were conducted in North America and Western Europe (75%). At baseline,
the mean and median age was 10 years (range 3–16) and the mean percentage of male partici-
pants was 77%. Fifty-three trials excluded children and adolescents with a comorbidity. Oppo-
sitional defiant disorder was the most common comorbidity (mean 44% of participants at
baseline among studies reporting data), followed by conduct disorder (21%). In terms of meth-
odological quality (S3 Table), 100 trials (52.6%) had a high risk of bias for at least one criterion,
85 trials (44.7%) had an unclear risk of bias and 5 trials (2.6%) had a low risk of bias. Ninety-
six trials (50.5% of all trials; 76.8% of trials evaluating pharmacological interventions) were
funded by drug companies. We obtained unpublished supplementary information for 42 of
the included trials (19 from manufacturer documents, 18 from trial registry/regulatory docu-
ments, 3 from investigators, and 2 other sources).
Treatment of ADHD in children and adolescents: A network meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0180355 July 12, 2017 8 / 31
Figs 1–4 (and S2 Fig) presents the evidence networks of eligible treatment comparisons for
the network meta-analyses. Placebo, stimulants (such as methylphenidate), non-stimulants
(such as atomoxetine) and behavioural therapy were most often investigated (103, 77, 55, and
28 trials, respectively). The networks also included psychological interventions such as cogni-
tive training and neurofeedback (20 trials), other pharmacological interventions (19 trials),
and complementary and alternative medicine (26 trials in monotherapy and 12 trials in combi-
nation with stimulants).
Findings from network meta-analysis
Summaries from all network meta-analyses are provided below for each outcome.
Findings for treatment response. Treatment response (efficacy) was reported in 8,916 of
19,398 patients from a total of 113 trials evaluating 26 classes of interventions or control condi-
tions. Low quality evidence suggests that behavioural therapy alone, stimulant monotherapy,
and non-stimulant monotherapy seemed significantly more efficacious than placebo (Table 1
and Fig 5). Antidepressants seemed also associated with greater response compared with pla-
cebo, but the evidence was very limited; only 128 participants received antidepressants
(Table 1). Stimulant monotherapy seemed superior to behavioural therapy alone, cognitive
training and non-stimulant monotherapy. Behavioural therapy in combination with stimu-
lants seemed also superior to placebo, cognitive training, neurofeedback, stimulant or non-
stimulant monotherapy (Fig 5). The combination of stimulants and non-stimulants seemed
significantly better than placebo, behavioural therapy alone, cognitive training, neurofeedback
Fig 1. Evidence network diagram for primary outcome of efficacy among therapeutic classes. Solid lines represent direct comparisons within
randomised trials. Nodes in blue represent controls. Nodes in green represent psychological interventions. Nodes in grey represent pharmacological
interventions. Nodes in purple represent complementary and alternative medicine interventions. Nodes in red represent combined interventions. Size of
node is proportional to number of randomised trials, and thickness of line connecting nodes is proportional to number of randomised trials directly
comparing the two treatments. PUFA = polyunsaturated fatty acids.
https://doi.org/10.1371/journal.pone.0180355.g001
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and monotherapy with stimulants or non-stimulants; however, only 480 participants received
combined therapy with stimulants and non-stimulants across 4 trials and the results might be
overestimated (very low quality of evidence).
Findings for treatment acceptability. The acceptability outcome (all-cause discontinua-
tion) was observed in a total of 4,822 of 22,961 patients from a total of 171 trials evaluating 32
classes of interventions or control conditions. Low to very low quality evidence suggests that
behavioural therapy alone and stimulant monotherapy showed the best profile of acceptability,
leading to significantly reduced chance of discontinuation compared to placebo (Table 2 and
Fig 5). Non-stimulant monotherapy or in combination with stimulants seemed better accepted
than placebo (very low quality of evidence). Behavioural therapy in combination with stimu-
lants seemed also superior to placebo, cognitive training, stimulant or non-stimulant mono-
therapy (very low quality of evidence) (Fig 5).
Cognitive training, neurofeedback, antipsychotics and complementary and alternative
medicine (such as dietary therapy, polyunsaturated fatty acids, amino acids, minerals, herbal
therapy, homeopathy, and physical activity) did not have greater effect on the primary out-
comes of efficacy and acceptability compared with placebo; the effects of these interventions
were not significant or were very imprecise (Table 2 and Table 3 and S6 Table, S7 Table).
Fig 2. Evidence network diagram for primary outcome of efficacy among individual therapies. Solid lines represent direct
comparisons within randomised trials. Nodes in blue represent controls. Nodes in green represent psychological interventions. Nodes in
grey represent pharmacological interventions. Nodes in purple represent complementary and alternative medicine interventions. Nodes
in red represent combined interventions. Size of node is proportional to number of randomised trials, and thickness of line connecting
nodes is proportional to number of randomised trials directly comparing the two treatments. AMPH = amphetamine. ATX = atomoxetine.
CLON = clonidine. GUAN = guanfacine. MODAF = modafinil. CARBA = carbamazepine. BUP = bupropion. DESIP = desipramine.
REBOX = reboxetine. VENLAF = venlafaxine. RISP = risperidone. THIO = thioridazine. L-CARN = L-carnitine. HYP = hypericum. C, P, T
training = child, parent and/or teacher training. P training = parent training. C training = child training. T training = teacher training. WM
training = working memory training.
https://doi.org/10.1371/journal.pone.0180355.g002
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Findings for comparisons amongst commonly prescribed medications. Results from
network meta-analyses performed at the agent level for commonly prescribed medications are
presented in Table 3 and Fig 6. Methylphenidate, amphetamine, atomoxetine, guanfacine, clo-
nidine and modafinil seemed significantly more efficacious than placebo (though we have less
confidence in the effects of clonidine and modafinil based upon GRADE ratings). Methylphe-
nidate and amphetamine seemed more efficacious than atomoxetine and guanfacine. In terms
of acceptability, methylphenidate and clonidine seemed superior to placebo, whereas methyl-
phenidate and clonidine seemed better accepted than atomoxetine (even though limited evi-
dence for clonidine based on numbers of studies and patients available).
Findings for secondary outcomes. Estimated effects for the secondary outcomes of toler-
ability (discontinuations due to adverse events), serious adverse events and specific adverse
events are presented in S8 Table.
Discontinuations due to adverse events were reported in 740 of 18,863 patients from a total
of 105 trials. Very low quality evidence suggests that stimulants, non-stimulants and the com-
bination of stimulants and non-stimulants were each well tolerated compared to placebo (OR
2.38, 95% CrI 1.45–3.99; 3.11, 1.99–5.08; and 4.54, 1.10–20.41, respectively).
Stimulants (OR 8.01, 95% CrI 5.75–11.34), non-stimulants (OR 4.70, 3.41–6.62), combina-
tions of stimulants and non-stimulants (OR 6.25, 1.97–19.11), antidepressants (OR 4.01, 1.63–
10.17) and other unlicensed drugs (OR 3.64, 1.59–8.67) produced anorexia (2,440 events in
15,856 patients from 81 trials); whereas stimulants (OR 21.64, 11.92–42.28), non-stimulants
(OR 10.31, 6.13–18.31) and other unlicensed drugs (OR 7.08, 1.71–31.97) led to weight loss
(710 events in 6,453 patients from 34 trials).
Fig 3. Evidence network diagram for primary outcome of acceptability among therapeutic classes. Solid lines represent direct comparisons within
randomised trials. Nodes in blue represent controls. Nodes in green represent psychological interventions. Nodes in grey represent pharmacological
interventions. Nodes in purple represent complementary and alternative medicine interventions. Nodes in red represent combined interventions. Size of
node is proportional to number of randomised trials, and thickness of line connecting nodes is proportional to number of randomised trials directly
comparing the two treatments. PUFA = polyunsaturated fatty acids.
https://doi.org/10.1371/journal.pone.0180355.g003
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Stimulants led to unspecified sleep disturbances (OR 6.02, 95% CrI 2.81–14.45; 371 events
in 2,125 patients from 22 trials), whereas regimens containing either stimulants (OR 3.99,
2.90–5.55), non-stimulants (OR 1.55, 1.12–2.19) or both (OR 3.81, 1.70–8.23), and other unli-
censed drugs (OR 7.18, 3.20–18.27) caused insomnia (1,068 events in 11,722 patients from 49
trials).
Treatment estimates for serious adverse events (96 events in 9,212 patients from 32 trials)
and anxiety (256 events in 2,961 patients from 21 trials) were non-significant or were highly
imprecise. Given the limited number of trials reporting data on syncope, this outcome was not
evaluated in the network meta-analyses.
Table 3 presents safety of commonly prescribed medications compared with methylpheni-
date. Amphetamine was associated with an increased the risk of weight loss compared with
methylphenidate. In terms of anorexia, methylphenidate was worse than atomoxetine and
guanfacine. For insomnia, methylphenidate was better than amphetamine but worse than
atomoxetine.
In terms of cardiovascular events, a limited number of trials reported similar outcome defi-
nitions on vital signs for different pharmacological interventions. For example, some studies
reported the following: an increase in blood pressure (183 events, 3034 patients and 13 trials);
a decrease in blood pressure (77 events, 1675 patients and 7 trials); an increase in heart rate
Fig 4. Evidence network diagram for primary outcome of acceptability among individual therapies. Solid lines represent direct
comparisons within randomised trials. Nodes in blue represent controls. Nodes in green represent psychological interventions. Nodes in
grey represent pharmacological interventions. Nodes in purple represent complementary and alternative medicine interventions. Nodes
in red represent combined interventions. Size of node is proportional to number of randomised trials, and thickness of line connecting
nodes is proportional to number of randomised trials directly comparing the two treatments. AMPH = amphetamine. ARIP = aripiprazole.
ATX = atomoxetine. CLON = clonidine. GUAN = guanfacine. MODAF = modafinil. CARBA = carbamazepine. BUP = bupropion.
DESIP = desipramine. REBOX = reboxetine. VENLAF = venlafaxine. RISP = risperidone. THIO = thioridazine. L-CARN = L-carnitine.
HYP = hypericum. HOMEO = homeopathy. C, P, T training = child, parent and/or teacher training. P training = parent training. C
training = child training. T training = teacher training. WM training = working memory training.
https://doi.org/10.1371/journal.pone.0180355.g004
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Table 1. Network meta-analysis for efficacy. Summary of treatment effects compared with placebo.
Trials Events and
participants
Class effect, OR (95% CrI) Individual effect, OR (95% CrI)
Controls
Placebo 65 929/4070 Reference Reference
Control (e.g., usual care) 8 148/545 1.99 (0.98–4.15); Very low-quality 1.29 (0.65–2.59); Very low-quality
Waiting list 5 25/121 0.57 (0.20–1.62); Very low-quality 0.29 (0.10–0.85)a; Very low-quality
Psychological interventions
Behavioural therapy 15 396/1016 2.97 (1.53–5.88)a; Low-quality -
Parent training 8 128/357 - 1.19 (0.50–2.77); Very low-quality
Child, parent and/or teacher training 8 254/535 - 2.73 (1.41–5.39)a; Low-quality
Cognitive training 2 7/65 0.70 (0.12–3.87); Very low-quality -
Working memory training 1 1/27 - 0.34 (0.01–5.82); Very low-quality
Attention training 1 6/38 - 4.17x1012 (1.63–12.44x1028)b;
Very low-quality
Other psychotherapies 1 10/32 7.02 (1.56–32.59)a; Very low-quality -
Neurofeedback 4 26/110 1.96 (0.52–8.26); Very low-quality -
Neurofeedback/theta-beta training 2 23/86 - 1.61x1013 (4.57–23.91x1028)b;
Very low-quality
Pharmacological interventions
Stimulants 53 3464/5831 6.21 (4.89–7.96)a; Low-quality -
Methylphenidate 40 2279/3836 - 5.26 (4.09–6.82)a; Low-quality
Amphetamine 9 1017/1628 - 7.45 (5.10–11.09)a; Low-quality
Non-stimulants 40 2447/4741 3.95 (3.13–5.07)a; Low-quality -
Atomoxetine 27 1547/3162 - 3.63 (2.81–4.73)a; Low-quality
Guanfacine 10 837/1461 - 3.29 (2.27–4.82)a; Low-quality
Clonidine 4 63/118 - 3.96 (1.89–8.41)a; Very low-quality
Antidepressants 6 69/128 8.52 (3.95–18.96)a; Very low-quality -
Bupropion 1 8/22 - 2.41 (0.48–11.63); Very-low quality
Desipramine 2 36/58 - 36.76 (9.17–214.0)a; Very-low
quality
Venlafaxine 1 12/19 - 4.07 (0.73–22.36); Very-low quality
Reboxetine 1 5/17 - 3.58 (0.57–22.11); Very-low quality
Antipsychotics 1 8/41 1.36 (0.34–5.38); Very low-quality -
Thioridazine 1 8/41 - 1.04 (0.28–3.78); Very-low quality
Other unlicensed drugs 6 248/572 3.80 (2.04–7.14)a; Very low-quality -
Modafinil 5 245/547 - 5.51 (3.04–10.32)a; Very-low
quality
Carbamazepine 1 3/25 - 0.18 (0.02–1.20); Very-low quality
Complementary and alternative medicine
interventions
Dietary therapy 2 43/65 2.07x107 (0.46x103-13.01x1021)b;
Very low-quality
-
Polyunsaturated fatty acids (or PUFAs) 3 41/124 2.14 (0.83–5.57); Very low-quality -
Omega-3 and -3/6 fatty acids 3 41/124 - 1.99 (0.85–4.82); Very-low quality
Amino acids 1 9/58 1.19 (0.25–5.71); Very low-quality -
L-carnitine 1 9/58 - 1.20 (0.29–5.22); Very-low quality
Minerals 2 49/220 2.93 (0.90–10.15); Very low-quality -
Zinc 1 45/202 - 2.42 (0.80–7.67); Very-low quality
Iron 1 4/18 - 2.71x1010 (3.34–9.19x1023)b; Very
low-quality
(Continued )
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(242 events, 5258 patients and 25 trials); a decrease in heart rate (87 events, 1972 patients and 9
trials); palpitations (23 events, 1366 patients, and 8 trials); and QT prolongation (64 events,
2234 patients, and 8 trials). Given this wide variability of reporting of cardiovascular events,
network meta-analysis for these specific events was considered not feasible.
Additional analyses. The full details of the additional analyses including sensitivity analy-
ses, subgroup analyses, model fit evaluations and small study effect bias assessments are reported
in the report S8 Table. Overall, it was noted that the results were not substantially different when




Class effect, OR (95% CrI) Individual effect, OR (95% CrI)
Herbal therapy 2 13/52 0.59 (0.17–1.99); Very low-quality -
St. John’s wort (Hypericum perforatum) 1 11/27 - 1.00 (0.23–4.26); Very-low quality
Ginkgo biloba 1 2/25 - 0.21 (0.02–1.35); Very low-quality
Combined interventions
Stimulants plus behavioural therapy 8 283/521 13.62 (6.83–27.93)a; Very low-quality -
Methylphenidate plus parent training 1 1/4 - 55.63 (3.18–29.52x102)a; Very low-
quality
Methylphenidate plus child, parent and/or
teacher training
5 187/282 - 15.82 (8.06–32.80)a; Very-low
quality
Stimulants plus non-stimulants 4 313/480 15.18 (7.50–31.46)a; Very low-quality -
Methylphenidate plus clonidine 1 29/33 - 21.91 (5.52–105.4)a,b;
Very-low quality
Non-stimulants plus behavioural therapy 4 86/163 6.05 (2.39–15.27)a; Very low-quality -
Atomoxetine plus parent training 1 18/50 - 2.48 (0.51–11.79); Very-low quality
Atomoxetine plus child, parent and/or teacher
training
3 68/113 - 5.53 (2.19–14.06)a; Very-low
quality
Stimulants plus antipsychotics plus
behavioural therapy
1 63/84 18.19 (4.10–83.33)a,b; Very low-
quality
-
Stimulants plus antipsychotics 2 33/54 10.32 (3.49–32.11)a,b; Very low-
quality
-
Methylphenidate plus thioridazine 1 8/41 - 5.97 (1.90–19.59)a,b;
Very-low quality
Stimulants plus other psychotherapies 1 31/59 15.42 (3.38–70.31) a,b; Very low-
quality
-
Stimulants plus polyunsaturated fatty
acids (or PUFAs)
2 47/50 16.81 (3.45–101.6) a,b; Very low-
quality
-
Methylphenidate plus omega-3/6 fatty acids 2 47/50 - 15.68 (3.43–87.0)a,b; Very-low
quality
Stimulants plus minerals 1 11/20 18.67 (3.15–116.0)a,b; Very low-
quality
-
Methylphenidate plus zinc 1 11/20 - 15.73 (2.94–85.29)a,b; Very low-
quality
Stimulants plus herbal therapy 1 26/33 10.15 (1.97–54.8)a,b;
Very low-quality
-
Methylphenidate plus ginkgo biloba 1 26/33 - 8.65 (1.94–40.79)a,b;
Very low-quality
Results are odds ratios (OR) with 95% credible Intervals and quality of evidence. An OR < 1 favours placebo (that is, more response events occur with
placebo that with other intervention).
ap < 0.05.
bExtremely wide credible intervals owing to small patient and trial numbers and frequent events among treatment arm.
https://doi.org/10.1371/journal.pone.0180355.t001
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in network meta-regression models. We excluded studies with high risk of bias and small studies,
but analyses may have led to insufficient statistical power for different treatment comparisons.
Primary analyses were influenced by short-term trials, with very limited information on long-
term effects in a subgroup analysis examining duration of treatment. No differences in conclu-
sions were observed in sensitivity analyses including the dosage and type of formulations of stim-
ulant medications. There was generally a better trade-off between model fit and complexity
when consistency was assumed. Measure of model fit suggested the presence of potential signifi-
cant inconsistency in a small number of cases: for acceptability (consistency model
DIC = 1855.73 versus inconsistency model DIC = 1881.88) and for tolerability (842.87 versus
851.00, respectively) (S9 Table), limiting the conclusiveness of findings for these endpoints. Data
were double-checked, and in both cases we could not identify any important covariate that dif-
fered across comparisons. Small study effect bias was quantitatively assessed, but inadequate
numbers of included trials with direct comparisons prevented us from drawing firm conclusions
from funnel plots and statistical tests (S10 Table, S3 Fig). Results on the primary outcomes for
the frequentist pairwise meta-analysis comparisons (for both the class effects as well as the indi-
vidual interventions) are provided in online supplement (see S10 Table). Overall, these analyses
suggested no conclusive evidence in direct estimates of treatment effects when comparing thera-
pies using placebo as the reference comparator.
Fig 5. Network meta-analyses for efficacy and acceptability of classes of pharmacological and psychological interventions. Data in blue represents
efficacy (treatment response). Data in red represents acceptability (all-cause discontinuation). Results are the ORs in the column-defining treatment compared with
the ORs in the row-defining treatment. For efficacy (acceptability), ORs higher than 1 favour the row-defining treatment. For acceptability, ORs lower than 1 favour
the row-defining treatment. Significant results are in bold and underscored. PBO = placebo. CONT = control. WL = waiting list. BEHAV = behavioural therapy.
COGN = cognitive training. NF = neurofeedback. STI = stimulants. N-STI = non-stimulants. AD = antidepressants. A-PSY = antipsychotics. O-DRU = other
unlicensed drugs. STI+BEHAV = stimulants+behavioural therapy. N-STI+BEHAV = non-stimulants+behavioural therapy. STI+N-STI = stimulants+non-stimulants.
OR = Odds ratio. CI = credibility interval.
https://doi.org/10.1371/journal.pone.0180355.g005
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Placebo 92 1406/5202 Reference Reference
Control (e.g., usual care) 17 79/819 0.55 (0.32–0.95)a; Very low-
quality
0.55 (0.32–0.98)a; Very low-quality
Waiting list 10 28/290 0.33 (0.15–0.70)a; Very low-
quality
0.30 (0.13–0.69)a; Very low-quality
Psychological interventions
Behavioural therapy 25 224/1385 0.58 (0.33–0.99)a; Very low-
quality
-
Parent training 16 124/742 - 0.69 (0.35–1.36); Very low-quality
Child, parent and/or teacher training 9 54/569 - 0.37 (0.17–0.80)a; Low-quality
Child training 2 48/205 - 0.25 (0.04–1.98); Very low-quality
Teacher training 1 4/28 - 0.76 (0.08–8.49); Very low-quality
Cognitive training 10 49/339 1.32 (0.71–2.52); Very low-
quality
-
Working memory training 6 27/198 - 1.75 (0.75–4.14); Very low-quality
Attention training 3 19/126 - 0.65 (0.22–1.92); Very low-quality
Behavioural therapy with cognitive training 1 3/26 3.39 (0.60–19.58); Very low-
quality
4.08 (0.69–24.66); Very low-quality
Neurofeedback 10 38/271 0.59 (0.31–1.14); Very low-
quality
-
Neurofeedback/theta-beta training 9 34/225 - 0.40 (0.19–0.82)a; Very low-quality
Pharmacological interventions
Stimulants 65 847/4778 0.67 (0.54–0.83)a; Low-
quality
-
Methylphenidate 55 585/3196 - 0.59 (0.46–0.75)a; Low-quality
Amphetamine 8 255/1433 - 0.78 (0.52–1.18); Very low-quality
Non-stimulants 52 1420/5817 0.81 (0.67–0.97)a; Very low-
quality
-
Atomoxetine 37 857/3844 - 0.85 (0.68–1.07); Very low-quality
Guanfacine 9 439/1449 - 0.79 (0.54–1.14); Very low-quality
Clonidine 6 71/298 - 0.40 (0.20–0.78)a; Very low-quality
Antidepressants 7 23/208 0.99 (0.44–2.28); Very low-
quality
-
Bupropion 3 11/114 - 1.54 (0.39–6.76); Very low-quality
Desipramine 2 6/58 - 0.70 (0.17–2.89); Very low -quality
Venlafaxine 1 1/19 - 0.64 (0.02–19.78); Very low-quality
Reboxetine 1 5/17 - 0.73 (0.12–4.44); Very low-quality
Antipsychotics 4 11/108 1.25 (0.43–3.63); Very low-
quality
-
Risperidone 2 5/42 - 0.56 (0.13–2.77); Very low-quality
Thioridazine 1 5/41 - 3.01 (0.57–17.81); Very low-quality
Aripiprazole 1 1/25 - 0.61 (0.02–25.34); Very low-quality
Other unlicensed drugs 7 133/585 0.73 (0.42–1.29); Very low-
quality
-
Modafinil 6 127/560 - 0.67 (0.37–1.24); Very low-quality
Carbamazepine 1 6/25 - 0.69 (0.11–4.27); Very low-quality
Complementary and alternative medicine
interventions
(Continued )
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Dietary therapy 3 13/85 0.79 (0.23–2.76); Very low-
quality
-
Elimination diet 3 13/85 - 0.77 (0.23–2.64); Very low-quality
Polyunsaturated fatty acids (or PUFAs) 9 92/442 1.09 (0.68–1.74); Very low-
quality
-
Omega-3 and -3/6 fatty acids 9 92/442 - 1.06 (0.66–1.71); Very low-quality
Amino acids 4 20/121 0.59 (0.24–1.44); Very low-
quality
-
L-carnitine 3 19/101 - 0.66 (0.25–1.75); Very low-quality
Minerals 3 111/248 1.14 (0.49–2.72); Very low-
quality
-
Zinc 2 109/230 - 1.05 (0.42–2.62); Very low-quality
Iron 1 2/18 - 26.79 (0.19–1.03x106)b; Very low-
quality
Herbal therapy 4 6/131 0.53 (0.15–1.88); Very low-
quality
-
St. John’s wort (Hypericum perforatum) 1 1/27 - 0.41 (0.01–6.11); Very low-quality
Ginkgo biloba 1 2/25 - 0.57 (0.05–6.67); Very low-quality
Ginseng 1 0/35 - 5.31x10-4 (5.70x10-12–0.69)b; Very
low-quality
Pine bark (extract) 1 3/44 - 1.33 (0.12–44.24); Very low-quality
Homeopathy 2 10/52 0.56 (0.18–1.73); Very low-
quality
0.56 (0.17–1.77); Very low-quality
Physical activity (exercise) 1 3/37 0.44 (0.07–2.19); Very low-
quality
0.48 (0.07–2.75); Very low-quality
Combined interventions
Stimulants plus behavioural therapy 13 109/699 0.37 (0.21–0.67)a; Low-
quality
-
Methylphenidate plus parent training 2 19/68 - 0.50 (0.18–1.44); Very low-quality
Methylphenidate plus child training 3 37/185 - 0.18 (0.02–1.74); Very low -quality
Methylphenidate plus child, parent and/or teacher
training
7 38/362 - 0.24 (0.12–0.50)a; Vey low-quality
Stimulants plus non-stimulants 7 85/529 0.47 (0.27–0.81)a; Low-
quality
-
Methylphenidate plus atomoxetine 1 1/9 - 1.00 (0.03–48.87); Very low-quality
Methylphenidate plus clonidine 3 12/73 - 0.32 (0.13–0.77)a; Very low-quality
Non-stimulants plus behavioural therapy 3 22/114 1.00 (0.37–2.84); Very low-
quality
-
Atomoxetine plus parent training 1 14/50 - 0.87 (0.21–3.74); Very low-quality
Atomoxetine plus child, parent and/or teacher
training
2 8/64 - 1.23 (0.29–6.03); Very low-quality
Stimulants plus antipsychotics plus
behavioural therapy
1 23/84 0.65 (0.19–2.37); Very low-
quality
-
Stimulants plus antipsychotics 2 4/54 0.99 (0.21–4.19); Very low-
quality
-
Methylphenidate plus thioridazine 1 3/42 - 1.61 (0.25–10.33); Very low-quality
Stimulants plus neurofeedback 2 12/76 0.37 (0.13–1.05); Very low-
quality
-
Methylphenidate plus neurofeedback 2 12/76 - 0.30 (0.10–0.89)a; Very low-quality




Treatment of ADHD in children and adolescents: A network meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0180355 July 12, 2017 17 / 31
Discussion
ADHD is one of the most commonly diagnosed and treated psychiatric disorders in child-
hood. In many Western countries, the prescribing rates have increased dramatically, with wide
variations in medical practice [53–56] that have led to remarkable controversies and public
debate around the clinical (and social) management of ADHD [57–60]. Our analysis of 190
studies that enrolled 26,114 participants randomly assigned to 52 different interventions
(grouped in 32 therapeutic classes) has evaluated the comparative effects of multiple pharma-
cological and non-pharmacological treatments used in children and adolescents with ADHD.
Our main findings have potential implications for informing evidence-based treatment
selection, but also establishing recommendations in clinical practice guidelines as well as the
future design of new studies. Some treatments for the management of ADHD differed in both
clinical and statistical aspects. In terms of response, behavioural therapy (alone or in combina-
tion with stimulants), stimulants and non-stimulants seemed significantly more efficacious
than placebo; stimulants seemed superior to behavioural therapy, cognitive training and non-
stimulants; and behavioural therapy in combination with stimulants seemed superior to mono-
therapy with stimulants or non-stimulants. Among single drug agents, methylphenidate, amphet-
amine, atomoxetine, guanfacine, clonidine and modafinil seemed significantly more efficacious
than placebo (even though less clear confidence with clonidine and modafinil). Methylphenidate
and amphetamine seemed more efficacious than atomoxetine and guanfacine. In terms of accept-
ability, behavioural therapy and stimulants (and their combination), showed the best profile of
acceptability leading to significantly fewer discontinuations that did placebo. Methylphenidate








Methylphenidate plus elimination diet 1 10/53 - 0.52 (0.13–2.00); Very low-quality
Stimulants plus polyunsaturated fatty acids (or
PUFAs)
3 9/111 0.34 (0.12–0.94)a; Very low-
quality
-
Methylphenidate plus omega-3/6 fatty acids 3 9/111 - 0.31 (0.11–0.84)a; Very low-quality
Stimulants plus amino acids 1 1/20 0.65 (0.02–34.56); Very low-
quality
-
Methylphenidate plus L-carnitine 1 1/20 - 0.50 (0.01–17.26); Very low-quality
Stimulants plus minerals 2 3/42 0.36 (0.05–1.97); Very low-
quality
-
Methylphenidate plus zinc 2 3/42 - 0.31 (0.05–1.68); Very low-quality
Stimulants plus herbal therapy 1 2/33 0.28 (0.03–2.08); Very low-
quality
-
Methylphenidate plus ginkgo biloba 1 2/33 - 0.23 (0.02–1.75); Very low-quality
Stimulants plus vitamins 1 15/23 1.49 (0.35–6.67); Very low-
quality
-
Methylphenidate plus vitamin B9 1 15/23 - 1.32 (0.30–5.94); Very low-quality
Stimulants plus physical activity 2 5/33 0.50 (0.09–2.76); Very low-
quality
-
Methylphenidate plus exercise 2 5/33 - 0.25 (0.02–3.93); Very low-quality
Results are odds ratios (OR) with 95% credible Intervals and quality of evidence. An OR > 1 favours placebo (that is, fewer events occur with placebo that
with other intervention).
ap < 0.05.
bExtremely wide credible intervals owing to small patient and trial numbers and rare events among treatment arm.
https://doi.org/10.1371/journal.pone.0180355.t002
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accepted than atomoxetine (even though limited evidence for clonidine). Most of the efficacious
pharmacological treatments (particularly, stimulants) were associated with anorexia, weight loss
and insomnia.
One of the most important clinical implications is that behavioural therapy, particularly
given by parents and with active child and teacher involvement, is the only non-pharmacologi-
cal intervention that was found to be associated with statistically significant benefits in our
analyses. Cognitive training, neurofeedback, dietary therapy (such as restricted elimination diet),
polyunsaturated fatty acids, amino acids, minerals, herbal therapy, homeopathy, and physical
activity cannot be recommended as evidence-based interventions for global functioning and
core ADHD symptoms until better evidence of their comparative efficacy is reported in well-
designed and conducted clinical trials. However, a healthy, balanced diet and regular exercise
should be emphasised for all children and adolescents, including those with ADHD [7]. Stimu-
lants such as methylphenidate and amphetamine may represent the best options amongst the
pharmacological interventions for ADHD, and non-stimulants such as atomoxetine, guanfacine


























































































































































































Results are odds ratios (OR) with 95% credible Intervals and quality of evidence. For efficacy, an OR < 1 favours methylphenidate (that is, more response
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and (less studied) clonidine may be considered secondary treatment options, respectively. Other
unlicensed medications have gained popularity in the mental health treatment of young people
(such as modafinil, antidepressants such as bupropion and antipsychotic agents), but the evi-
dence for these therapies (not indicated in ADHD) is currently very limited. Similarly, concerns
have been raised about the benefit-risk profile of the use in ADHD of these agents outside of
approved indications [40,61–64].
Our systematic review suggests that treatment effects are larger when behavioural therapy is
combined with stimulants (with very low quality of evidence). The clinical decision to combine
these interventions should be driven by the symptoms presented, the needs of the children and
their family and the availability of healthcare services. The value of combined treatment for
ADHD is recognized as an area of interest because it might lead to potential beneficial effects
in different domains [65]. Combining behavioural therapy with stimulants may enhance atten-
tional processes and reduce impulsive responding, and may be a way of reducing the dosage
and duration of pharmacological treatment, and thus addressing concerns about the potential
harms associated with the use of pharmacotherapy [9,65]. The Multimodal Treatment for chil-
dren with ADHD (MTA) study, a randomised trial that compared stimulant methylphenidate,
intensive behavioural therapy, and combination of both methylphenidate with intensive beha-
vioural therapy with a community control, is considered the largest (n = 579 participants) and
perhaps the most methodologically sound investigation of combination treatment for ADHD
Fig 6. Network meta-analyses for efficacy and acceptability of commonly prescribed medications for ADHD. Data in blue represents efficacy
(treatment response). Data in red represents acceptability (all-cause discontinuation). Results are the ORs in the column-defining treatment compared with
the ORs in the row-defining treatment. For efficacy (acceptability), ORs higher than 1 favour the row-defining treatment. For acceptability, ORs lower than 1
favour the row-defining treatment. Significant results are in bold and underscored. PBO = placebo. MPH = methylphenidate. AMPH = amphetamine.
ATX = atomoxetine. CLON = clonidine. GUAN = guanfacine. MODAF = modafinil. BUP = bupropion. OR = Odds ratio. CI = credibility interval.
https://doi.org/10.1371/journal.pone.0180355.g006
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[19,66]. In line with our findings, results of the MTA study suggested a benefit from combina-
tion treatment over stimulant monotherapy when categorical measures of excellent response
were used [67], but the effects were considered small in magnitude and subsequent trials of
smaller sample size reported conflicting results [68–71]. Our finding that combination of stim-
ulants and non-stimulants treatment (such as methylphenidate plus clonidine, atomoxetine,
or guanfacine) appears to be effective for ADHD may challenge some guidance on the man-
agement of ADHD, as commonly no clear recommendations are made for (or against) com-
bining these two pharmacological treatments. In our opinion, concerns about widespread
adoption of this therapeutic strategy could be justified despite the potential benefits of combi-
nation drug regimens, because available information on the balance between potential benefits
and safety are incompletely characterized in the biomedical literature [72–77].
There are multiple and diverse clinical practice guidelines worldwide for the management
of ADHD [9–11,40,78–80], such as those developed by the National Institute for Health and
Care Excellence (NICE) [9] and by the Scottish Intercollegiate Guidelines Network (SIGN) in
the UK [78], and by the American Academy of Pediatrics (AAP) [79] and the American Acad-
emy of Child and Adolescent Psychiatry (AACAP) [80] in the US. Some of the most important
differences between them are that US guidelines recommend the use of pharmacological treat-
ment for children with mild ADHD or pre-school children; conversely, the UK guidelines
state that pharmacological treatment should be reserved for those ADHD children with severe
symptoms and impairment, or moderate levels of impairment who have refused non-pharma-
cological interventions, or whose symptoms have not responded sufficiently to behavioural
interventions. Generally, some of these guidelines recognise that if pharmacological treatment
is prescribed, it should be provided in conjunction with behavioural therapy. Thus, consider-
ing the overall benefit-risk balance of the multiple interventions, the interpretation of our find-
ings may support a stepwise approach following UK recommendations, which suggests that
increased access to behavioural therapy and pharmacological treatment (as indicated) would
improve symptomatic and functional outcomes for children and adolescents with ADHD.
Along with broad recognition that data from some clinical trials and treatment compari-
sons were sparse, and that more and higher-quality data could improve estimations and rec-
ommendations, aspects of the general approach of previous systematic reviews and meta-
analyses [12–17,81–83] were challenged. For example, two recent Cochrane systematic reviews
have suggested that stimulants such as amphetamines [12] and methylphenidate [13] may
improve ADHD core symptoms compared to placebo (or no intervention) in children and
adolescents; but overall quality of the evidence ranged from low to very low on most outcomes.
However, no network meta-analyses to compare the relative effects of all existing interventions
have been performed to address this knowledge gap. In contrast to the traditional meta-analy-
sis methods which focus on reducing the evaluation to a single pair-wise comparison, network
meta-analyses allow multiple intervention comparisons to be made. The strengths of this
review also include the completeness of the search including multiple databases and trial regis-
tries, forward searching of unpublished data and hand searching of the grey literature, risk of
bias assessment and reporting of confidence in treatment effects when interpreting each ther-
apy comparison. We also used an a priori published protocol and followed established report-
ing guidelines [29,30].
There are some limitations to be noted regarding our study. We used established methods
[32–34] to leverage a large number of existing systematic reviews and meta-analyses, to iden-
tify relevant studies. Although we believe this technique has performed well, our review may
have missed studies due to differences in the eligibility criteria and coverage of the retrieved
reviews. Similar to other reviews and meta-analyses [12–17,81–83], there is methodological
and clinical heterogeneity in the included trials in terms of trial design, patient populations,
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and outcome measurement. Caution should be used when interpreting findings, considering
the fact that not all treatments (particularly, non-pharmacological treatments) are represented
in the trials that formed the evidence base. The primary outcomes of efficacy and acceptability
were the most commonly and consistently reported outcomes across the network of trials.
However, as we did not control the risks of type I errors in meta-analyses of primary outcomes,
the presence of potential false positive findings cannot be excluded. As with individual clinical
trials and pairwise meta-analyses, secondary outcomes and additional analyses (e.g., sensitivity
analyses and subgroups analyses) should be regarded as exploratory and multiple testing
[84,85] issues need to be considered when results are interpreted. Our review does not provide
evidence that supports any stimulant over another, and does not reveal any significant differ-
ences between short-acting and long-acting formulations. Insufficient patient numbers and
events to form well connected networks limited the analyses that could be conducted to
account for dosage and intensity of non-stimulants and non-pharmacological treatments in
the absence of more studies.
Although we adopted reproducible definitions, the heterogeneous reporting of events in
studies posed a major challenge. None of the trials examined and reported all the outcomes of
interest. The overall quality of the network meta-analyses evidence ranged from low to very
low as assessed by the GRADE approach (the quality or confidence of evidence ratings were
rated down by serious concerns of risk of bias in the randomised trials, imprecision of treat-
ment effect estimates, and potential inconsistency) (see S7 Table). In fact, results on the pri-
mary outcomes for both the network meta-analyses and pairwise meta-analyses include small
number of studies relative to the number of comparisons considered, resulting in low confi-
dence in estimates for many key analyses and comparisons. Therefore, further high-quality tri-
als are likely to have an important impact on the confidence of treatment effects estimates and
may change the interpretation of our findings. At the study level, many trials appear to have
several reporting or methodological issues, and an additional limitation was the very small
sample sizes. Many trials had a high risk of bias (53%) or unclear risk of bias (45%) for at least
one criterion, and most trials were funded by industry (50% of all trials; 77% of trials evaluat-
ing pharmacological treatments). Inclusion of funding source as a standard item for rating
sponsorship bias and conflicts of interest [13,86] could make the risk of bias even more appar-
ent than that reported in our review. In our opinion, these issues require further pragmatic
action at the levels of planning, funding, conduct, and reporting of randomised trials [85,87–
90]. Preexisting therapies, the settings in which psychological interventions were undertaken,
how they were carried out, and potential factors responsible for response or failure are not
always clearly reported in many ADHD trials and presents a challenge to treatment classifica-
tion and knowledge translation. To the extent possible, we pursued sensitivity analyses includ-
ing study-level covariates in network meta-regression models to infer about transitivity/
consistency and to establish the robustness of our findings. Overall, we show that our results
are robust to a variety of estimation procedures, but these analyses may be underpowered. We
used study-level data instead of individual patient data, so the small number of studies limited
the additional analyses that could be conducted to account for effect modifiers in the absence
of patient-level data. There is also a limited ability of studies with a mean duration of about 12
weeks to inform long-term (chronic) management and treatment decisions. We selected for our
primary efficacy outcome of response rate to use a dichotomous rather than continuous measure
(e.g. standardized mean difference), because from a clinical perspective, syntheses of continuous
outcomes measured on different scales can be difficult to interpret [30,31]. However, a limitation
of this method is that there can be a substantial information loss when continuous outcome vari-
ables are dichotomised. Dichotomisation may also increase the risk of a positive result being a
false positive [91–93]. Furthermore, we were unable to investigate other important outcomes
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such as remission and recovery (e.g. no longer meeting the criteria for the diagnosis of ADHD),
potential serious adverse effects (e.g. ischaemic heart disease, hepatic damage and suicidal idea-
tion/behaviour), or other aspects such as drugs abuse/misuse, resource allocation and costs [6–
8,94–99]. Finally, our results might have limited generalizability (social, economic, educational
and cultural context), because studies were mostly conducted in children and adolescents from
Western countries. Consequently, our results should be interpreted with caution given the cave-
ats mentioned above.
There is still room for improvement in the design, conduct and reporting of trials in the
field. The clinical research agenda of ADHD is incomplete and needs better designed and
reported randomised trials to assess the benefits and harms of the multiple interventions avail-
able for the management of ADHD in the young people. In this respect, ADHD complex path-
ogenesis implicates multiple factors of a diverse nature that should be considered in clinical
research [6–8]. A pertinent research agenda [100,101] which views ADHD dimensionally, but
also integrating mental health services and interventions into priority care strategies, should
be established in order to appreciate which treatments are best for ADHD children of different
ages and in different communities. There is an urgent need for long-term randomised trials at
low-risk of bias and with sufficient numbers of participants. It is important that future clinical
trials report completely the methods and results for all outcomes of interest (including adverse
events) using standardised outcome measures at similar time points to ensure include in future
evidence syntheses. Reporting guidelines such as SPIRIT (Standard Protocol Items: Recom-
mendations for Intervention Trials) [102] and CONSORT (Consolidated Standards of Report-
ing Trials) [103–106] should be rigorously adopted and implemented for study protocols and
study reports, respectively.
In conclusion, although the quality of evidence is not strong, clinical differences may exist
between the pharmacological and non-pharmacological treatments commonly used for the
management of ADHD. Behavioural therapy and pharmacological treatment may improve the
symptoms of ADHD and global functioning in the short-term. Our findings can help clini-
cians, healthcare providers, parents, and caregivers make informed decisions regarding treat-
ment selection for the management of ADHD. An open and honest discussion with parents
and older children about uncertainties of available treatments and the balance between bene-
fits, costs, and potential harms should be established before starting treatment. In addition,
there is an urgent need for high-quality randomised trials of the multiple treatments for
ADHD in children and adolescents.
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